Explore

Trendline Trendline
Brenntag Launches Byphar Brand to Enhance Biopharmaceutical Manufacturing

Brenntag Launches Byphar Brand to Enhance Biopharmaceutical Manufacturing

Brenntag Launches Byphar Brand to Enhance Biopharmaceutical Manufacturing
Trendline Trendline
Eli Lilly Ends Partnership with Rigel Pharmaceuticals, Impacting RIPK1 Inhibitor Development

Eli Lilly Ends Partnership with Rigel Pharmaceuticals, Impacting RIPK1 Inhibitor Development

Eli Lilly Ends Partnership with Rigel Pharmaceuticals, Impacting RIPK1 Inhibitor Development
Trendline Trendline
Kallyope's Elismetrep Shows Promise in Migraine Treatment at Neurology Meeting

Kallyope's Elismetrep Shows Promise in Migraine Treatment at Neurology Meeting

Kallyope's Elismetrep Shows Promise in Migraine Treatment at Neurology Meeting
Trendline Trendline
Calluna Pharma Completes Enrollment in Global Phase 2 Study for Pulmonary Fibrosis Treatment

Calluna Pharma Completes Enrollment in Global Phase 2 Study for Pulmonary Fibrosis Treatment

Calluna Pharma Completes Enrollment in Global Phase 2 Study for Pulmonary Fibrosis Treatment
Trendline Trendline
Roche's Fenebrutinib Shows Promise in Reducing MS Relapses and Brain Lesions

Roche's Fenebrutinib Shows Promise in Reducing MS Relapses and Brain Lesions

Roche's Fenebrutinib Shows Promise in Reducing MS Relapses and Brain Lesions
Trendline Trendline
Eli Lilly Ends Partnership with Rigel Pharmaceuticals, Impacting RIPK1 Drug Development

Eli Lilly Ends Partnership with Rigel Pharmaceuticals, Impacting RIPK1 Drug Development

Eli Lilly Ends Partnership with Rigel Pharmaceuticals, Impacting RIPK1 Drug Development
Trendline Trendline
Plus Therapeutics Initiates Manufacturing Activities for CNS Cancer Drug REYOBIQ

Plus Therapeutics Initiates Manufacturing Activities for CNS Cancer Drug REYOBIQ

Plus Therapeutics Initiates Manufacturing Activities for CNS Cancer Drug REYOBIQ
Trendline Trendline
Tortugas Neuroscience Secures $106M for CNS Drug Development

Tortugas Neuroscience Secures $106M for CNS Drug Development

Tortugas Neuroscience Secures $106M for CNS Drug Development
Trendline Trendline
Merck Shares Decline Following Unsuccessful Kidney Cancer Drug Trial

Merck Shares Decline Following Unsuccessful Kidney Cancer Drug Trial

Merck Shares Decline Following Unsuccessful Kidney Cancer Drug Trial
Trendline Trendline
Merck and Eisai's Keytruda Triplet Fails to Improve Survival in Kidney Cancer Patients

Merck and Eisai's Keytruda Triplet Fails to Improve Survival in Kidney Cancer Patients

Merck and Eisai's Keytruda Triplet Fails to Improve Survival in Kidney Cancer Patients
Trendline Trendline
Merck and Eisai Announce Results of Phase 3 Trial for Renal Cell Carcinoma Treatment

Merck and Eisai Announce Results of Phase 3 Trial for Renal Cell Carcinoma Treatment

Merck and Eisai Announce Results of Phase 3 Trial for Renal Cell Carcinoma Treatment
Trendline Trendline
MSD and Eisai Face Setback in Kidney Cancer Trial with Welireg

MSD and Eisai Face Setback in Kidney Cancer Trial with Welireg

MSD and Eisai Face Setback in Kidney Cancer Trial with Welireg